Bio News

U.S.-based Navisys detected all pathogenic genomic abnormalities in five leukemia samples using electronic genome mapping (EGM) technology.
Researchers at Augusta University said EGM concordantly confirmed all abnormalities identified by standard cytogenetic testing and optical genome mapping in four cases of acute myeloid leukemia and one case of chronic myeloid leukemia.
Based on this proof-of-concept study, Navisys plans to further evaluate EGM in larger and more diverse populations.

BIOBOOK TEAM
biobookmedia@biobook.co.krCosentyx Approved by FDA for 11th Indication: Polymyalgia Rheumatica
Delonix and Singapore’s A*STAR IDL to Collaborate on Vaccine Against Drug-Resistant Klebsiella pneumoniae
Brazilian Health Regulatory Agency Approves Oral Plaque Psoriasis Treatment Icotyde
Medtronic to Acquire Contego Medical for $380 Million
Brazilian Health Regulatory Agency Approves Botox for Masseter Muscle Prominence
Roche’s oral SERD Itovebi wins FDA approval, cutting risk of progression by 62%